# Effects of Artificial Intelligence Clinical Decision Support Tools on Complications Following Percutaneous Coronary Intervention

## TL;DR

This study shows that using AI tools during heart procedures can significantly reduce complications and hospital stays.

## Contribution

The study demonstrates the effectiveness of AI clinical decision support tools in reducing post-PCI complications and length of stay.

## Key findings

- The incidence of contrast-induced acute kidney injury dropped from 10% to 2.18%.
- Bleeding complications decreased from 2.15 to 1.54 per month.
- Average hospital length of stay decreased from 3.44 to 1.79 days.

## Abstract

Artificial intelligence (AI) models have been created that incorporate unique patient characteristics to risk stratify patients undergoing cardiac catheterization with percutaneous coronary intervention (PCI). The most frequent complications following PCI are contrast-induced acute kidney injury (CI-AKI) and postprocedural bleeding, resulting in increased adverse outcomes, length of stay (LOS), and health care costs. Our study investigates the impact of AI clinical decision support tools on these events.

A retrospective review of patients undergoing PCI at our institution from April 2023 to March 2024 was performed. All patients had an ePRISM (Terumo Health Outcomes AI clinical decision support tool) generated risk assessment and maximum contrast volume recommendation reported during procedure time-out. Statistical analysis was performed to determine the incidence of post-PCI CI-AKI, bleeding events, and LOS.

A total of 642 patients were analyzed. The incidence of CI-AKI significantly declined from a baseline of 10% to an average of 2.18% (P < .0001). Of the remaining CI-AKI, 92.9% occurred in hospitalized patients. The incidence of bleeding complications declined from a baseline incidence of 2.15 per month to an average of 1.54 per month. Our institution’s average LOS declined from a baseline of 3.44 to 1.79 days.

AI clinical decision support tools can be effectively incorporated into clinical practice. ePRISM successfully risk-stratified patients undergoing PCI for CI-AKI and bleeding events and gave meaningful recommendations which resulted in a significant reduction in adverse events and LOS.